PCM
VOR icon

Pinz Capital Management’s Vor Biopharma VOR Stock Holding History

Pinz Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-244
Closed -$210K – 565
2021
Q1 		$210K Buy
+244
New +$206K 0.06% 105

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pinz Capital Management's VOR Position: Q2 2021 in Review

Pinz Capital Management sold out of Vor Biopharma (VOR) in Q2 2021, closing a stake of 244 shares — an estimated $210K sold.

Pinz Capital Management first reported a position in VOR in Q1 2021 and held it in 1 quarter. The position peaked at $210K in Q1 2021. 51 funds tracked by Wall St. Rank hold VOR as of Q2 2021.

  • Pinz Capital Management reported no remaining Vor Biopharma position as of Q2 2021 after selling out during the quarter.
  • Pinz Capital Management sold 244 Vor Biopharma shares in Q2 2021, an estimated $210K.
  • Pinz Capital Management first reported a position in Vor Biopharma in Q1 2021 and held it in 1 quarter.
  • Pinz Capital Management's Vor Biopharma position peaked at $210K in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2021.

Based on Pinz Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.